Journal profile · Radiology, Nuclear Medicine & Medical Imaging
Cancer Radiotherapie
ISSN 1278-3218 · eISSN 1769-6658 · Elsevier Masson · FRANCE · Bimonthly · Founded 1997
Cancer Radiotherapie: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.22; hybrid open access; APC about USD 2,190; median 50 days to acceptance (98 articles, last 24 months); community-reported acceptance: easy (Elsevier website: 64%); 114 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer Radiotherapie is published by Elsevier Masson and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Advanced Radiotherapy Techniques, Head and Neck Cancer Studies and Prostate Cancer Diagnosis and Treatment, together about 27.5% of its articles. Its main subfields are Pulmonary and Respiratory Medicine. (generated from OpenAlex topic counts and CAS ranking data)
Offıcial journal of the Société française de radiothérapie oncologique (SFRO).Cancer/Radiothérapie is an English language medium for the publication of research in radiation therapy. The journal aims at reporting major findings in cancer research and radiation treatments: technology, physics, radiobiology, and clinical radiotherapy. The journal publishes eight issues per year including a special issue devoted to the proceedings of the annual meeting of the Société française de radiothérapie oncologique (SFRO).
From the journal's Aims & Scope
Research area (LetPub): Radiology, Nuclear Medicine & Medical Imaging
Editor-in-chief Cyrus ChargariPublisher website
Editorial board by country: none in mainland China; most named France 39, Belgium 4, India 3, Italy 2 (48 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Advanced Radiotherapy TechniquesPhysics and Astronomy15.1%
- Head and Neck Cancer StudiesMedicine6.5%
- Prostate Cancer Diagnosis and TreatmentMedicine6%
- Lung Cancer Diagnosis and TreatmentMedicine5.9%
- Brain Metastases and TreatmentMedicine5.3%
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology5.3%
- Glioma Diagnosis and TreatmentMedicine4.6%
- Prostate Cancer Treatment and ResearchMedicine4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Radiology, Nuclear Medicine & Medical Imaging | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Radiology, Nuclear Medicine & Medical Imaging | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Radiology, Nuclear Medicine & Medical Imaging | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.22LetPub ·
- Impact factor (publisher)
- 1.3Publisher website ·
- CiteScore 2026-06
- 3.1LetPub ·
- CiteScore (publisher)
- 3.1Publisher website ·
- SJR 2026-06
- 0.48LetPub ·
- SNIP 2026-06
- 0.67LetPub ·
- h-index
- 29LetPub ·
- h-index
- 53OpenAlex ·
- i10-index
- 861OpenAlex ·
- 2-year mean citedness
- 1.52OpenAlex ·
- Self-citation rate
- 15.4%LetPub ·
- Share of gold OA articles
- 19.74%LetPub ·
Volume
- Articles per year
- 108LetPub ·
Articles by year OpenAlex count · 6,151 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 47 | 21 | 8 |
| 2025 | 114 | 36 | 152 |
| 2024 | 101 | 44 | 239 |
| 2023 | 125 | 62 | 357 |
| 2022 | 105 | 54 | 325 |
| 2021 | 232 | 77 | 1,825 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
50 daysMedian, submission to acceptance · P25–P75 28 days – 90 days
- Acceptance to online
- median 141 days (98 articles)
- Submission to online
- median 193 days
- Sample
- 98 articles with submission and acceptance dates (187 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- 64%LetPub ·
- Acceptance rate (publisher)
- 40%Publisher website ·
- Submission to first decision
- 4 daysPublisher website ·
- First decision after review
- 41 daysPublisher website ·
- Submission to acceptance
- 48 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 2,190 / EUR 2,000 / GBP 1,760 / JPY 271,630 | — | — | |
| Publisher website | USD 2,730 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open Access
Article Publishing Charge (APC): USD 2,730 (excluding taxes). The amount you pay may be reduced during submission if applicable.Review this journal’s open access policy.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier Masson
- Country or region
- FRANCE
- Language
- French
- Frequency
- Bimonthly
- Founded
- 1997
- ISSN
- 1278-3218
- Electronic ISSN
- 1769-6658
- Society / sponsor
- Société française de radiothérapie oncologique
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Cancer Radiotherapie
What CAS zone is Cancer Radiotherapie in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Radiotherapie is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology / Radiology, Nuclear Medicine & Medical Imaging. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Radiotherapie?
The latest impact factor listed by LetPub is 1.22; CiteScore 3.1, h-index 53.
How long does peer review take at Cancer Radiotherapie?
Based on the dates recorded on 98 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 50 days (interquartile range 28–90 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Easy (Elsevier website: 64%)”; the journal's website gives an acceptance rate of 40%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Cancer Radiotherapie based?
Of the 48 board members whose country the journal's board page names, none are in mainland China; the countries named most often are France (39), Belgium (4) and India (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Cancer Radiotherapie?
According to LetPub and DOAJ records, Cancer Radiotherapie is indexed in SCIE and Scopus.
Is Cancer Radiotherapie open access, and what is the APC?
Cancer Radiotherapie is a hybrid journal. For open-access publication: APC about USD 2,190.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .